Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

This study, called CHANCES, tracks whether certain cancer treatments — particularly platinum-based chemotherapy or PARP inhibitor drugs — may later lead to the development of blood disorders. Researchers will take blood samples over time to look for early signs of these changes. **You may be eligible if...** - You have or have had ovarian, fallopian tube, or peritoneal cancer and completed at least 5 cycles of platinum-based chemotherapy - OR you have any solid tumor diagnosis and have taken a PARP inhibitor drug (such as olaparib or niraparib) for at least 4 months - OR you have already been diagnosed with a blood disorder such as clonal hematopoiesis or a therapy-related blood cancer - You have a life expectancy of more than 6 months **You may NOT be eligible if...** - Your life expectancy is less than 6 months Talk to your doctor to see if this trial is right for you.